Literature DB >> 2528306

Mivacurium-induced neuromuscular blockade following single bolus doses and with continuous infusion during either balanced or enflurane anesthesia.

C A Shanks1, R J Fragen, D Pemberton, J A Katz, M E Risner.   

Abstract

Mivacurium chloride (BW B1090U) was administered to 72 patients during their elective surgery. The eight groups (nine subjects per cell) in the 2 x 2 x 2 study design differed in three factors: the size of the mivacurium bolus dose administered, whether or not this dose was followed by an infusion of mivacurium, and in the technique used for the maintenance of anesthesia. Four groups received a single bolus dose of mivacurium, 0.15 mg/kg, and the remaining four groups received mivacurium, 0.25 mg/kg, administered iv in 15 s. Precisely 2 min later, tracheal intubation was attempted. Conditions were judged to be good or excellent on most occasions, but intubation was not possible for two of the patients in the low-dose and one in the high-dose groups. Four groups, two at each bolus dose, received no additional mivacurium: there was a dose-dependent decrease in the rate of spontaneous recovery following the bolus dose. The other subdivision of groups was the use of either barbiturate-nitrous oxide-narcotic (balanced) anesthesia, or enflurane-nitrous oxide anesthesia; the anesthetic technique did not affect the pattern of spontaneous recovery from either bolus dose. Four groups, again two at each bolus dose, subsequently received an infusion of mivacurium, adjusted to depress the twitch response by approximately 95%. Infusion rates averaged 6.0 micrograms.kg-1.min-1 in the groups receiving balanced anesthesia and 4.2 micrograms.kg-1.min-1 for those receiving enflurane anesthesia. Recovery following administration by infusion was slower than that observed following a bolus dose of mivacurium, 0.15 mg/kg but did not differ between the anesthetic groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528306     DOI: 10.1097/00000542-198909000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

Review 1.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  [Effects of different doses of edrophonium antagonism of mivacurium-induced neuromuscular block in the presence of nitrous oxide, propofol, and alfentanil anesthesia].

Authors:  J Ripart; P Drolet; L Perreault; M Girard
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

3.  Dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block during N2O-enflurane-alfentanil anaesthesia.

Authors:  J Marcotte; P Drolet; L Perreault; M Girard
Journal:  Can J Anaesth       Date:  1995-10       Impact factor: 5.063

Review 4.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 5.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 6.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Edrophonium requirements for reversal of deep neuromuscular block following infusion of mivacurium.

Authors:  D R Miller; G Bryson; R J Martineau; J B Kitts; M Curran; P Bragg; J B Watson; K Hull; P Lindsay
Journal:  Can J Anaesth       Date:  1995-11       Impact factor: 5.063

Review 8.  New developments in nondepolarizing muscle relaxants.

Authors:  R K Mirakhur
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.